The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology/Oncology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Sun, 06 Sep 2026 10:19:29 GMT 2026 NEJM Group en-us 1440 A dying patient in a state psychiatric hospital has no access to a DNR order that would make the process as peaceful as possible — as the notorious Bedlam casts a shadow over mental health care to this day. https://www.nejm.org/doi/full/10.1056/NEJMp2600529?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2600529 Richard Elledge 2026-09-05 The Long Shadow of Bedlam In a phase 1–2 study of daraxonrasib, 54% of patients with RAS-mutant non–small-cell lung cancer had grade 3 or higher adverse events, mainly pneumonia, diarrhea, and rash; more than 30% of patients had a response. https://www.nejm.org/doi/full/10.1056/NEJMoa2504059?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2504059 Kathryn C. Arbour, Salman Punekar, Jia Luo, Melissa Johnson, Alexander Spira, Benjamin Herzberg, Alexander Starodub, David Sommerhalder, Joel Randolph Hecht, Ignacio Garrido-Laguna, Minal Barve, Sai-Hong Ignatius Ou, Sumit Kar, Lei Bao, Lin Tao, Rashmi Vora, Aparna Hegde, Andreas Saltos, Nilofer S. Azad, David S. Hong, the RMC-6236-001 Investigators* 2026-09-03 Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. https://www.nejm.org/doi/full/10.1056/NEJMoa2602804?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602804 Amir T. Fathi, Alexander E. Perl, Geoffrey G. Fell, Brian A. Jonas, Brittany K. Ragon, Alice S. Mims, Uma Borate, Gabriel N. Mannis, Karen Quillen, Maximilian Stahl, Brandon J. Aubrey, Paul Koller, Andrew S. Artz, Monzr M. Al Malki, Anthony S. Stein, Guido Marcucci, Mary Linton B. Peters, Timothy A. Graubert, Peter Westervelt, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela Hobbs, Rupa Narayan, Michelle H. Lee, Peter G. Miller, Alyssa L. Watson, Richard Hao, Abigail C. Marola, Jennifer Lombardi-Story, Shilton Dhaver, Michael R. Grunwald, Yi-Bin Chen, Matthew J. Weinstock, Andrew H. Matthews, Ian McGovern, Brent L. Wood, Christopher S. Hourigan, Donna S. Neuberg, Areej El-Jawahri, Ibrahim Aldoss 2026-09-03 Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia This review summarizes the management of pulmonary nodules, with an emphasis on nodule type, imaging follow-up, cancer risk, and strategies to balance timely diagnosis with avoidance of unnecessary procedures. https://www.nejm.org/doi/full/10.1056/NEJMcp2515063?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2515063 Matthew E.J. Callister, Gerard A. Silvestri 2026-09-03 Pulmonary Nodules I first treated a patient with leukemia with the so-called “7+3” regimen (a 7-day continuous infusion of cytarabine plus three daily infusions of an anthracycline, usually daunorubicin)1 more than 50 years ago during my residency. To be candid, I had little understanding of what I was doing but... https://www.nejm.org/doi/full/10.1056/NEJMe2607967?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2607967 Charles A. Schiffer 2026-09-03 Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups. https://www.nejm.org/doi/full/10.1056/NEJMc2603114?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2603114 Yu-Hang Cheng, Ke Shang, Chuan Qin, Ming-Hao Dong, Yun-Hui Chu, Ke Huang, Zhi-Cheng Mei, Jun Xiao, Zi-Hao Liang, Yu-Hang Li, Wei Wang, Dai-Shi Tian 2026-09-03 Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. https://www.nejm.org/doi/full/10.1056/NEJMoa2604461?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604461 Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M. Memmott, Ozan Yazici, Meili Sun, Catherine A. Shu, Elvire Pons-Tostivint, Yun Fan, Gonzalo Fernandez-Hinojal, Elaine Shum, Mengzhao Wang, Federica Bertolini, D. Ross Camidge, Chengzhi Zhou, Ludovic Doucet, Qunying Hong, Jian Fang, Dingzhi Huang, Bo Jin, Yan Yu, Lorenzo Antonuzzo, Denis Moro-Sibilot, Jaafar Bennouna, Gilberto de Castro Jr., Li Zheng, John V. Heymach, the WU-KONG28 Investigators* 2026-08-20 First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations This review summarizes the pathogenesis and treatment of myeloproliferative neoplasms, highlighting the role of driver mutations, inflammation, and emerging targeted therapies that may achieve durable disease modification. https://www.nejm.org/doi/full/10.1056/NEJMra2507867?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2507867 Isabelle Plo, William Vainchenker 2026-08-20 Myeloproliferative Neoplasms A proposed reclassification of medical marijuana products as Schedule III drugs would address only two of the three key barriers to research on marijuana’s safety and effectiveness for various indications. https://www.nejm.org/doi/full/10.1056/NEJMp2606593?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2606593 Rebecca L. Haffajee, Robert A. Mikos, Ziva D. Cooper 2026-08-20 Marijuana Rescheduling — A Game Changer for Research? An 82-year-old man was brought to the ED after being “found down.” One week earlier, he had returned from a 1-month visit to Chad. A peripheral-blood smear showed ring-form trophozoites within erythrocytes. https://www.nejm.org/doi/full/10.1056/NEJMicm2603855?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2603855 Emilie Karoline Van Pee, Johan Van Laethem 2026-08-20 Severe Plasmodium falciparum Malaria Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. https://www.nejm.org/doi/full/10.1056/NEJMoa2602628?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602628 Yi-Long Wu, Maximilian Hochmair, Yi Yang, Xue-Ning Yang, Masahiro Tsuboi, Luis Paz-Ares, James Chih-Hsin Yang, Lin Wu, Hye Ryun Kim, Damian T. Rieke, Melissa Johnson, Benjamin Besse, Nivedita Sharma, Patricia Maeda, Patrick Peterson, Boris Kin Lin, Bente Frimodt-Moller, Jonathan Goldman, Alexander Drilon, the LIBRETTO-432 Trial Investigators† 2026-08-13 Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. https://www.nejm.org/doi/full/10.1056/NEJMoa2604657?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604657 Roberto Mina, Meral Beksac, Paula Rodríguez-Otero, Wenming Chen, María-Victoria Mateos, Jian Li, Philippe Moreau, Yael C. Cohen, Chang-Ki Min, Tomas Jelinek, Jing Christine Ye, Hila Magen, Samuel M. Rubinstein, Weijun Fu, Vania Hungria, Guldane Cengiz Seval, Joao Samuel Farias, Jakub Radocha, Senem Maral, Mehmet Turgut, Youngil Koh, Daniel O’Leary, Jayr Schmidt Filho, Raymond Thertulien, Gang An, Shang-Yi Huang, Sebastian Grosicki, Agata Tyczyńska, Rahul Banerjee, Matthew J. Pianko, Joaquín Martínez-López, Pawel Steckiewicz, Dai Maruyama, Kentaro Fukushima, Albert Oriol, Jordi Lopez Pardo, Hartmut Goldschmidt, Charlotte Pawlyn, Aurore Perrot, Elena Zamagni, Meletios A. Dimopoulos, Leo Rasche, Jaszianne Tolbert, William Terry, Christelle Courtoux, Xiao Liu, Sandra Y. Vasey, Kaitlyn Connors, Mariacristina Festa, Christoph Heuck, Angélique Langlois, Lisa O’Rourke, Jiangxiu Zhou, Xiang Qin, Jiashen Lu, Joy Gong, Diego Vieyra, Peter M. Voorhees, the MonumenTAL-3 Investigators* 2026-08-13 Talquetamab–Daratumumab in Relapsed or Refractory Myeloma A 55-year-old man with a smoking history of 10 pack-years presented with 2 years of an enlarging, painless lump below his right ear. A previously unnoticed smaller mass in the left parotid gland was seen on examination. https://www.nejm.org/doi/full/10.1056/NEJMicm2604482?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2604482 Xiaoling Pan, Cheng Lin 2026-08-13 Warthin Tumors A 61-year-old man with prolonged neutropenia after chemotherapy for AML was evaluated for persistent fever despite antimicrobial therapy. Physical examination was notable for a skin macule with central necrosis on the chest. https://www.nejm.org/doi/full/10.1056/NEJMicm2603271?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2603271 Hanna Osawa, Takahisa Fujino 2026-08-13 Disseminated Fusariosis In a child with advanced nephroblastoma, T-cell therapy targeting preferentially expressed antigen in melanoma led to a 69% tumor reduction, with molecular, metabolic, and histologic evidence of complete remission at 200 days. https://www.nejm.org/doi/full/10.1056/NEJMc2605154?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2605154 Katharina Mair, Corinne Rossi, Jens H. Westhoff, Thomas G.P. Grünewald, Jens-Peter Schenk, Alexandra Tuch, Esther Wahlbrink, Stefanie Volz, Kendra K. Maass, Sophia Scheuermann, Simon Krost, Fabienne Engelmann, Barbara C. Jones, Joachim B. Kunz, Inga Harting, Erik Winter, Patrick Guenther, Anita Schmitt, Carsten Müller-Tidow, Liane Preussner, Cedrik M. Britten, Robert J. Autry, David T.W. Jones, Stefan M. Pfister, Dirk Jäger, Andreas E. Kulozik, Olaf Witt, Patrick Schmidt, Christian M. Seitz 2026-08-13 PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2603878?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603878 Mary-Ellen Taplin, Martin Gleave, Neal D. Shore, Angela Lopez-Gitlitz, Alexander Kretschmer, Eleni Efstathiou, Paul L. Nguyen, Ronaldo Damião, Toshiyuki Kamoto, Ashley Ross, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Álvaro Juárez Soto, Huihui Ye, Geoffrey Gotto, Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Branko Miladinovic, Sharon A. McCarthy, Christopher P. Evans, Adam S. Kibel, the PROTEUS Investigators* 2026-08-06 Perioperative Apalutamide in High-Risk Localized Prostate Cancer Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either... https://www.nejm.org/doi/full/10.1056/NEJMe2606250?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606250 Emmanuel S. Antonarakis 2026-08-06 A Watershed Moment in the Perioperative Treatment of Prostate Cancer A 60-year-old woman with stage II triple-negative breast cancer presented to the ED with a weeklong history of fevers, rigors, malaise, nonproductive cough, and nausea. https://www.nejm.org/doi/full/10.1056/NEJMcps2516922?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcps2516922 Hae Lin Cho, Nancy Berliner, Stephen Babcock, Yee-Ping Sun, Bruce Levy 2026-08-06 Consumed with Inflammation In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. https://www.nejm.org/doi/full/10.1056/NEJMoa2604126?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604126 Neeraj Agarwal, Nobuaki Matsubara, Arun A. Azad, Fred Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, Eric Voog, Neal D. Shore, Timuçin Çil, Christof Vulsteke, Hsiao-Jen Chung, Stefanie Zschäbitz, A. Douglas Laird, Xiaoxi Zhang, Prachi Nandoskar, Sarah Fenech Chetcuti, Fong Wang, Karim Fizazi 2026-07-30 PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. https://www.nejm.org/doi/full/10.1056/NEJMoa2603870?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603870 Cyrille Touzeau, Roberto Mina, Hang Quach, Vania Hungria, Divaya Bhutani, Wenming Chen, Swarup Kumar, Chakra Chaulagain, Meletios Athanasios Dimopoulos, Nizar J. Bahlis, Senem Maral, Niels W.C.J. van de Donk, Jayr Schmidt Filho, Khalid Saja, Raphael Teipel, Miki Ando, Wilfried Roeloffzen, Ombretta Annibali, Bradley Augustson, Cirino Botta, Michel Delforge, Emmanuelle Bourgeois, Gabriele Buda, Marek Hus, Aurore Perrot, Meir Preis, Meral Beksac, Ludek Pour, Sarah Farmer, Marta Nunes, Albert Oriol, Thomas Melchardt, Yu Hu, Max Flogegård, Dai Wang, Lixia Pei, Susan Wroblewski, Ingrid M. Ariës, Natalia A. Quijano Cardé, Tatiana Perova, Tertia de Jager, Tzu-Min Yeh, Veronique Vanquickelberghe, Priya Shah, Katherine Chastain, Rachel Kobos, Robin Carson, Ola Landgren, the MajesTEC-9 Trial Investigators* 2026-07-30 Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy